Chronic Obstructive Pulmonary DiseaseNCT07106086
Combined Effect of Scapulothoracic Mobilization With Buteyko Breathing on COPD (Chronic Obstructive Pulmonary Disease) Patients
A study testing Scapulothoracic mobilization and Buteyko breathing in people with Chronic Obstructive Pulmonary Disease, run by Rashid Latif Medical College at 1 site in Pakistan.
Trial summary
The objective of this study will be to determine the combine effect of scapulothoracic mobilization with Buteyko breathing on pulmonary parameters functional capacity and balance among COPD patient. Read more about this study
- Who is it for?
- Ages 40 to 65 years
- Conditions the study is for
- Chronic Obstructive Pulmonary Disease
- What is being tested?
- Scapulothoracic mobilization and Buteyko breathing
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 sitePakistan
- Study dates
- 20 Jul 2024to 30 Dec 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Clinically Diagnosed COPD is confirmed by diagnostic criteria of COPD (forced expiratory volume in 1 second [FEV1] <80% predicted, FEV1/forced vital capacity [FVC] <0.7 predicted) according to the international guideline and the ability to provide inform consent.
- Patients with Resting Respiratory Rate >_ 24
Who cannot join
- Patients diagnosed with a primary pulmonary vascular disease
- Patients diagnosed with severe psychiatric disorders and cognitive dysfunction
- Patients diagnosed severe auditory/visual impairments
- Patients diagnosed Musculoskeletal, Rheumatic ,Cardiac/Neurological disorder and Malignancies
- Patients diagnosed with skin, peripheral vascular disorder excluded
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Combined Effect of Scapulothoracic Mobilization With Buteyko Breathing on Pulmonary Parameters Functional Capacity and Balance Among COPD (Chronic Obstructive Pulmonary Disease) Patients
The objective of this study will be to determine the combine effect of scapulothoracic mobilization with Buteyko breathing on pulmonary parameters functional capacity and balance among COPD patient.
Read the detailed description
The study will be Randomized Clinical Trial which include forty (40) subjects clinically diagnosed according to Global Initiative for Obstructive Lung Disease (GOLD) standard of chronic obstructive pulmonary disease (COPD). Patients will be allocated into two groups i.e. Group A (20) and Group B (20). Group A scapulothoracic mobilization with Buteyko breathing (BBT) and Group B received Buteyko breathing (BBT). The Pulse oximeter will be used to evaluate Pulmonary parameters. The 6-meter walk test will be used to assess functional capacity. The Activities-specific balance confidence scale (ABC scale) will be used to assess Balance Confidence and Single leg stance (SLS) will be used to evaluate balance. The evaluation will be done on day one as pretreatment values and post-treatment values at the end of third week.
- Conditions
- Chronic Obstructive Pulmonary Disease
- Being tested
- Scapulothoracic mobilization, Buteyko breathing
- Keywords
- Balance, Breathing, COPD, Functional Capacity, Mobilization
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive, Respiratory Aspiration
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Scapulothoracic mobilizationOther
Scapulothoracic Mobilization and Buteyko Breathing Technique:
Subjects lay supine with arms crossed, hands on opposite scapulae. The interventionist stabilized elbows and applied pressure to shoulders, with one hand on the spine using a loose fist to mobilize vertebrae. Various spinal motions-rotation, flexion, lateral flexion, and translation-were assessed. In a lateral position, the subject bent both knees and placed the upper arm on a cushion. The interventionist stood close, placing fingers under the scapula's medial border.
Buteyko breathingOther
Buteyko Breathing: Subjects sat upright, relaxed respiratory muscles, and breathed gently through the nose. The sequence included calm nasal inhalation and exhalation using the diaphragm, followed by shallow inhalation and slow exhalation. A brief post-exhalation breath hold was added. The cycle was repeated for several minutes.
| Study group | Role | What they receive |
|---|---|---|
| Scapulothoracic mobilization with buteyko breathing | Experimental | Scapulothoracic mobilization with buteyko breathing Receives: Other: Scapulothoracic mobilization; Other: Buteyko breathing |
| Buteyko breathing | Active comparator | buteyko breathing Receives: Other: Buteyko breathing |
What is being measured
The primary outcome is the main question the study is designed to answer.
Oxygen Saturation
Oxygen saturation is measured by Pulse oximeter The gold standard for measuring arterial blood oxygen saturation (SaO₂) requires arterial blood sampling, but pulse oximetry provides a non-invasive estimate (SpO₂) widely used to detect hypoxemia.
Measured: Pre and 2 week Post intervention
Functional capacity
Functional Capacity is measured by 6- minute walk test. The 6-minute walk test (6MWT) is a well-known tool to measure ability to walk and endurance in the sub-maximal condition. The 6MWT is a exercise test that involves measuring the distance walked over a span of 6 minutes. Participants were encouraged to walk on a straight, flat surface as fast as possible for 6 minutes on a marked course, with pauses as necessary.
Measured: Pre and 2 week post intervention
Balance
The Balance is measured by Single leg stance test. Single Leg Stance (SLS). The SLS is a simple balance test where the participant stands on one leg for as long as possible (up to 60 seconds) with hands on hips. The test is performed first with eyes open, then with eyes closed. Longer duration indicates better balance. The SLS has demonstrated excellent reliability in individuals with COPD as well as in community-dwelling older adults.
Measured: Pre and 2 week post intervention
Secondary outcomes (2)
Respiratory rate
Respiratory rate is measured by Pulse oximeter Pulse oximetry can reliably estimate respiratory rate (RR) and is suitable for wearable use due to its compactness and cost-effectiveness.
Measured: Pre and Post 2 week intervention
Heart rate
Heart rate is measured by the Pulse oximeter. Normal resting heart rate ranges from 60-100 bpm, but it may fluctuate. COPD patients often show elevated resting HR. Pulse oximeters can effectively monitor HR.
Measured: Pre and Post 2 week intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Aug 2025
- Study start20 Jul 2024
- Primary completion20 Nov 2024
- Study completion30 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Chronic Obstructive Pulmonary DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Rashid Latif Medical College
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Aleena Waheed, Rashid Latif Medical College
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07106086
- Sponsor's protocol ID
- IRB/2023/130
- Status last verified
- Aug 2025
- First submitted
- 28 Jul 2025
- Last updated
- 6 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Not Decided yet
Publications
Jarhyan P, Hutchinson A, Khaw D, Prabhakaran D, Mohan S. Prevalence of chronic obstructive pulmonary disease and chronic bronchitis in eight countries: a systematic review and meta-analysis. Bull World Health Organ. 2022 Mar 1;100(3):216-230. doi: 10.2471/BLT.21.286870. Epub 2022 Jan 19.
PubMed 35261410Gore S, Blackwood J, Ziccardi T. Associations Between Cognitive Function, Balance, and Gait Speed in Community-Dwelling Older Adults with COPD. J Geriatr Phys Ther. 2023 Jan-Mar 01;46(1):46-52. doi: 10.1519/JPT.0000000000000323. Epub 2021 Jul 29.
PubMed 34334706Chen Y, Li P, Wang J, Wu W, Liu X. Assessments and Targeted Rehabilitation Therapies for Diaphragmatic Dysfunction in Patients with Chronic Obstructive Pulmonary Disease: A Narrative Review. Int J Chron Obstruct Pulmon Dis. 2022 Mar 3;17:457-473. doi: 10.2147/COPD.S338583. eCollection 2022.
PubMed 35273448Berriet AC, Beaumont M, Peran L, Le Ber C, Couturaud F. Effects of pulmonary rehabilitation on fear of falling in Chronic Obstructive Pulmonary Disease (COPD) patients: An observational study. Respir Med Res. 2022 Nov;82:100932. doi: 10.1016/j.resmer.2022.100932. Epub 2022 Jun 12.
PubMed 35878569Alqahtani JS. Prevalence, incidence, morbidity and mortality rates of COPD in Saudi Arabia: Trends in burden of COPD from 1990 to 2019. PLoS One. 2022 May 19;17(5):e0268772. doi: 10.1371/journal.pone.0268772. eCollection 2022.
PubMed 35588429Agusti A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, Bourbeau J, Han MK, Martinez FJ, Montes de Oca M, Mortimer K, Papi A, Pavord I, Roche N, Salvi S, Sin DD, Singh D, Stockley R, Lopez Varela MV, Wedzicha JA, Vogelmeier CF. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Eur Respir J. 2023 Apr 1;61(4):2300239. doi: 10.1183/13993003.00239-2023. Print 2023 Apr.
PubMed 36858443
Study at a glance
From the registry record, last updated by the sponsor on 6 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Combined Effect of Scapulothoracic Mobilization With Buteyko Breathing on Pulmonary Parameters Functional Capacity and Balance Among COPD (Chronic Obstructive Pulmonary Disease) Patients
- ClinicalTrials.gov ID
- NCT07106086
- Acronym / sponsor ID
- IRB/2023/130
- Conditions
- Chronic Obstructive Pulmonary Disease
- Keywords
- Balance, Breathing, COPD, Functional Capacity, Mobilization
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Rashid Latif Medical CollegeUniversity, hospital or other
- Study start
- 20 Jul 2024 (actual)
- Primary completion
- 20 Nov 2024 (actual)
- Study completion
- 30 Dec 2024 (actual)
- First posted
- 6 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study will be to determine the combine effect of scapulothoracic mobilization with Buteyko breathing on pulmonary parameters functional capacity and balance among COPD patient.
Detailed description
The study will be Randomized Clinical Trial which include forty (40) subjects clinically diagnosed according to Global Initiative for Obstructive Lung Disease (GOLD) standard of chronic obstructive pulmonary disease (COPD). Patients will be allocated into two groups i.e. Group A (20) and Group B (20). Group A scapulothoracic mobilization with Buteyko breathing (BBT) and Group B received Buteyko breathing (BBT). The Pulse oximeter will be used to evaluate Pulmonary parameters. The 6-meter walk test will be used to assess functional capacity. The Activities-specific balance confidence scale (ABC scale) will be used to assess Balance Confidence and Single leg stance (SLS) will be used to evaluate balance. The evaluation will be done on day one as pretreatment values and post-treatment values at the end of third week.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Scapulothoracic mobilization with buteyko breathing | Experimental | Other: Scapulothoracic mobilization, Other: Buteyko breathingScapulothoracic mobilization with buteyko breathing |
| Buteyko breathing | Active comparator | Other: Buteyko breathingbuteyko breathing |
Who may qualify
- Ages
- 40 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Clinically Diagnosed COPD is confirmed by diagnostic criteria of COPD (forced expiratory volume in 1 second [FEV1] <80% predicted, FEV1/forced vital capacity [FVC] <0.7 predicted) according to the international guideline and the ability to provide inform consent.
- Patients with Resting Respiratory Rate >_ 24
Key exclusion criteria (5 listed)
- Patients diagnosed with a primary pulmonary vascular disease
- Patients diagnosed with severe psychiatric disorders and cognitive dysfunction
- Patients diagnosed severe auditory/visual impairments
- Patients diagnosed Musculoskeletal, Rheumatic ,Cardiac/Neurological disorder and Malignancies
- Patients diagnosed with skin, peripheral vascular disorder excluded
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Scapulothoracic mobilizationScapulothoracic Mobilization and Buteyko Breathing Technique: Subjects lay supine with arms crossed, hands on opposite scapulae. The interventionist stabilized elbows and applied pressure to shoulders, with one hand on the spine using a loose fist to mobilize vertebrae. Various spinal motions-rotation, flexion, lateral flexion, and translation-were assessed. In a lateral position, the subject bent both knees and placed the upper arm on a cushion. The interventionist stood close, placing fingers under the scapula's medial border. | Other | Scapulothoracic mobilization with buteyko breathing |
| Buteyko breathingButeyko Breathing: Subjects sat upright, relaxed respiratory muscles, and breathed gently through the nose. The sequence included calm nasal inhalation and exhalation using the diaphragm, followed by shallow inhalation and slow exhalation. A brief post-exhalation breath hold was added. The cycle was repeated for several minutes. | Other | Buteyko breathing, Scapulothoracic mobilization with buteyko breathing |
Primary outcome
Oxygen Saturation
Time frame: Pre and 2 week Post intervention
Oxygen saturation is measured by Pulse oximeter The gold standard for measuring arterial blood oxygen saturation (SaO₂) requires arterial blood sampling, but pulse oximetry provides a non-invasive estimate (SpO₂) widely used to detect hypoxemia.
Functional capacity
Time frame: Pre and 2 week post intervention
Functional Capacity is measured by 6- minute walk test. The 6-minute walk test (6MWT) is a well-known tool to measure ability to walk and endurance in the sub-maximal condition. The 6MWT is a exercise test that involves measuring the distance walked over a span of 6 minutes. Participants were encouraged to walk on a straight, flat surface as fast as possible for 6 minutes on a marked course, with pauses as necessary.
Balance
Time frame: Pre and 2 week post intervention
The Balance is measured by Single leg stance test. Single Leg Stance (SLS). The SLS is a simple balance test where the participant stands on one leg for as long as possible (up to 60 seconds) with hands on hips. The test is performed first with eyes open, then with eyes closed. Longer duration indicates better balance. The SLS has demonstrated excellent reliability in individuals with COPD as well as in community-dwelling older adults.
2 secondary outcomes
Respiratory rate
Time frame: Pre and Post 2 week intervention
Heart rate
Time frame: Pre and Post 2 week intervention
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Aug 2025.
- Results publication: PubMed 35261410Jarhyan P, Hutchinson A, Khaw D, Prabhakaran D, Mohan S. Prevalence of chronic obstructive pulmonary disease and chronic bronchitis in eight countries: a systematic review and meta-analysis. Bull World Health Organ. 2022 Mar 1;100(3):216-230. doi: 10.2471/BLT.21.286870. Epub 2022 Jan 19.
- Results publication: PubMed 34334706Gore S, Blackwood J, Ziccardi T. Associations Between Cognitive Function, Balance, and Gait Speed in Community-Dwelling Older Adults with COPD. J Geriatr Phys Ther. 2023 Jan-Mar 01;46(1):46-52. doi: 10.1519/JPT.0000000000000323. Epub 2021 Jul 29.
- Results publication: PubMed 35273448Chen Y, Li P, Wang J, Wu W, Liu X. Assessments and Targeted Rehabilitation Therapies for Diaphragmatic Dysfunction in Patients with Chronic Obstructive Pulmonary Disease: A Narrative Review. Int J Chron Obstruct Pulmon Dis. 2022 Mar 3;17:457-473. doi: 10.2147/COPD.S338583. eCollection 2022.
- Results publication: PubMed 35878569Berriet AC, Beaumont M, Peran L, Le Ber C, Couturaud F. Effects of pulmonary rehabilitation on fear of falling in Chronic Obstructive Pulmonary Disease (COPD) patients: An observational study. Respir Med Res. 2022 Nov;82:100932. doi: 10.1016/j.resmer.2022.100932. Epub 2022 Jun 12.
- Results publication: PubMed 35588429Alqahtani JS. Prevalence, incidence, morbidity and mortality rates of COPD in Saudi Arabia: Trends in burden of COPD from 1990 to 2019. PLoS One. 2022 May 19;17(5):e0268772. doi: 10.1371/journal.pone.0268772. eCollection 2022.
- Results publication: PubMed 36858443Agusti A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, Bourbeau J, Han MK, Martinez FJ, Montes de Oca M, Mortimer K, Papi A, Pavord I, Roche N, Salvi S, Sin DD, Singh D, Stockley R, Lopez Varela MV, Wedzicha JA, Vogelmeier CF. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Eur Respir J. 2023 Apr 1;61(4):2300239. doi: 10.1183/13993003.00239-2023. Print 2023 Apr.
- Individual participant dataSharing planned: Undecided. Not Decided yet
Related trials for Chronic Obstructive Pulmonary Disease
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Chronic Graft Versus Host Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Scapulothoracic mobilization and Buteyko breathing in people with Chronic Obstructive Pulmonary Disease, run by Rashid Latif Medical College at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Oxygen Saturation (time frame: Pre and 2 week Post intervention). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07106086, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2025.